HC Wainwright Comments on Acasti Pharma Inc.’s Q2 2025 Earnings (NASDAQ:ACST)

Acasti Pharma Inc. (NASDAQ:ACST) – Research analysts at HC Wainwright dropped their Q2 2025 EPS estimates for Acasti Pharma in a research note issued to investors on Thursday, September 26th. HC Wainwright analyst O. Livnat now anticipates that the biopharmaceutical company will post earnings of ($0.34) per share for the quarter, down from their prior forecast of ($0.31). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Acasti Pharma’s current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Acasti Pharma’s Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($0.75) EPS, FY2028 earnings at $0.01 EPS and FY2029 earnings at $1.39 EPS.

Acasti Pharma (NASDAQ:ACST) last issued its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04.

Separately, Craig Hallum boosted their price target on shares of Acasti Pharma from $6.00 to $8.00 and gave the company a “buy” rating in a report on Thursday.

Acasti Pharma Trading Up 1.6 %

NASDAQ ACST opened at $3.12 on Monday. The company has a market cap of $29.32 million, a P/E ratio of -2.17 and a beta of 1.51. The company has a fifty day simple moving average of $2.59 and a 200 day simple moving average of $2.90. Acasti Pharma has a 1 year low of $1.98 and a 1 year high of $3.59.

Institutional Investors Weigh In On Acasti Pharma

An institutional investor recently raised its position in Acasti Pharma stock. AIGH Capital Management LLC grew its stake in shares of Acasti Pharma Inc. (NASDAQ:ACST) by 28.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 641,083 shares of the biopharmaceutical company’s stock after purchasing an additional 143,724 shares during the quarter. Acasti Pharma comprises about 0.6% of AIGH Capital Management LLC’s portfolio, making the stock its 26th biggest holding. AIGH Capital Management LLC owned about 6.82% of Acasti Pharma worth $1,883,000 as of its most recent filing with the Securities & Exchange Commission. 6.08% of the stock is currently owned by hedge funds and other institutional investors.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.